211At-MABG in Adults With Advanced Neuroendocrine Cancers

Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible for approved treatments. Phase 1 dose-escalation will follow a standard 3+3 design with an expansion cohort at the recommended phase two dose (RP2D).

NCT Number	NCT07661420
Lead Sponsor	University of Pennsylvania Collaborators: National Institutes of Health (NIH), National Cancer Institute (NCI)
Conditions	Pheochromocytoma, Paraganglioma, Neuroendocrine Tumors, Medullary Thyroid Cancer, Bronchial Carcinoid, Gastroenteropancreatic Neuroendocrine Neoplasm
Enrollment	16 participants
Start Date	2026-08-01
Primary Completion	2029-08-01 (estimated)
Study Completion	2032-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-22